Top ten fast-growing medicine enterprises in 2006

From: Medicine and Economics       Date: January 5, 2007
Conba’s Soaring again
Annual evaluation: ★★★★★ self-evaluation: ★★★★☆

【Power proof 】
From January to September in 2006, Conba Group’s income of major businesses amounts to 564.6997 million RMB, 7.15% lower against the same period of the previous year, but the total profits amounts to 44.5703 million RMB, 16.04% higher, including 34.2544 million RMB of net profits, 35.3% higher. The growth rate of Qianliekang’s sales is possible to stand at about 20% in 2006, with sales of the whole year reaching 260 million RMB; the sales of Wuling capsule is expected to reach 90 million RMB, with a growth rate of about 15% year on year. After the shareholding reform, the mother company of Conba has a much better control on the cost. Through 2006, the rate of cost for business of the mother company is probable to be limited around 37%. And with consolidated statements, the cost will be around 30%.

【power performance】
On August 28, 2004, a “hurricane” named Conba arrived in the medicine market in China. Five hundred days later, Qianliekang, a twenty-year old brand, which had never exceeded 100 million RMB in sales income, became the top brand in the market of medicine for prostate diseases with 260 million RMB. Conba set up a good example for old brand to become vigorous again. On August 28, 2006, the “hurricane” named Conba came again. At the first Summit forum on integration of production enterprises and sales companies, held in Hangzhou, Zhejiang, Conba demonstrated their new OTC species of medicine for nasal diseases, namely “Conba rhinitis dropping liquid” , with the concrete marketing strategy. This is really a good application of the ideal of integration producer and sales company.

【Remarks:】
Chemical medicine for prostate diseases is still popular, but the Chinese medicine has great potential. With the trend of aging, the market of medicine for prostate diseases has a bright future.